Ecological risk assessment of pharmaceuticals and endocrine disrupting compounds in Brazilian surface waters.

Pharmaceuticals and endocrine disrupting compounds are organic micropollutants that can cause adverse effects at low concentrations. Their occurrence in surface waters has been reported in several countries, including Brazil, at concentrations on the order of ngL-1, while the concentrations at which toxic effects are observed are often in the range of mg.L-1 to µg.L -1, however few studies have been undertaken to characterize risks they represent in Brazilian surface waters. Thus, the objective of this study was to evaluate the ecological risk to Brazilian surface waters caused by the presence of pharmaceuticals and natural and environmental estrogens. Twenty-nine pharmaceuticals, hormones and environmental estrogens were included in the risk assessment while twelve were discarded due to insufficient data availability. The endocrine disrupting compounds were the most frequently detected (39.8% of the reported concentrations), followed by non-steroidal anti-inflammatory drugs (16.3%), antibiotics (6.6%), antiseptics (5.1%), analgesics (5.1%), antihypertensives (4.6%), and to a lesser extent, lipid controllers, anticonvulsants, antidepressants, antihistamines, antivirals and corticosteroids. Bisphenol-A was the most frequently detected compound, followed by diclofenac, 17-ß-estradiol, 17-α-ethynilestradiol, naproxen, triclosan and 4-n-nonylphenol. Acute ecological risk was predicted in two thirds and chronic risk in one third of the water bodies surveyed. The presence of diclofenac or triclosan was determinant for acute risk while estrogenic hormones proved to be decisive for chronic risk. In addition to natural and synthetic endocrine disruptors, the pharmacological groups estimated to have the highest average associated risks were non-steroidal anti-inflammatory drugs, followed by anticonvulsants. No discharge limits exist for most of the compounds found to contribute to ecological risks, indicating the need for regulatory action by the proper Brazilian authorities.

Characterization of low-shrinkage dental composites containing methacrylethyl-polyhedral oligomeric silsesquioxane (ME-POSS).

The aim of this study was to characterize low-shrinkage dental composites containing methacrylethyl-polyhedral oligomeric silsesquioxane (ME-POSS). Four experimental composites were manufactured, two of which contained organic matrixes of BisGMA-TEGDMA (70/30 wt% - BGC) and BisEMA-TEGDMA (80/20 wt% - BEC). The two other experimental composites replaced BisGMA and BisEMA with 25 wt% of ME-POSS (BGP and BEP). The composites also contained 70 wt% of 0.7 µm silanized BaBSi particles. The following properties were evaluated: Degree of conversion (DC%), volumetric polymerization shrinkage (VS%), polymerization shrinkage stress (Pss), flexural strength (FS), Flexural modulus (FM), hardness (KHN), water sorption (Wsp), water solubility (Wsl), diffusion coefficient (D), and wear. The DC% was not influenced by the presence of ME-POSS, with BEC (75.6%) and BEP (74.8%) presenting higher DC% than BGC (60.6%) and BGP (55.6%). The ME-POSS-containing composites (BGP and BEP) presented significantly lower VS% and Pss. The FS ranged from 92.7 to 142.0 MPa and the FM from 3.6 to 10.3 GPa. ME-POSS did not influence the KHN. BEC and BEP presented lower Wsp and Wsl when compared to BGC and BGP. D ranged from 1.0 × 10-6 to 7.4 × 10-6 cm2 m-1. Incorporation of ME-POSS significantly decreased the wear for both binary matrices (p < 0.05). With the exception of FS and FM for BGP, the incorporation of ME-POSS decreased the VS% and Pss without jeopardizing the other properties of the experimental dental composites.

Lipoperoxidation and cyclooxygenase enzyme inhibitory piperidine alkaloids from Cassia spectabilis green fruits.

Phytochemical work in the search for bioactive metabolites from the methanolic extract of Senna spectabilis green fruits led to the isolation of a new piperidine alkaloid, (+)-3- O-feruloylcassine ( 1), in addition to the known (-)-spectaline ( 2) and (-)-3- O-acetylspectaline ( 3). The isolates were submitted to in vitro evaluation of lipoperoxidation (LPO) and cyclooxygenase enzymes (COX-1 and -2) inhibitory properties and showed moderate antioxidant activities (40-70%) at 100 ppm when compared to commercial standards BHT and vitamin E and moderate inhibition of COX-1 (ca . 40%) and marginal inhibition of COX-2 enzymes (<10%) at 100 ppm when compared to nonsteroidal anti-inflammatory drugs (NSAIDs) aspirin, rofecoxib, and celecoxib, respectively.